Meridian Bioscience, Inc. (VIVO)
| Market Cap | 971.19M |
| Revenue (ttm) | 299.16M |
| Net Income (ttm) | 70.14M |
| Shares Out | 43.10M |
| EPS (ttm) | 1.61 |
| PE Ratio | 13.97 |
| Forward PE | 15.82 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $22.50 |
| Previous Close | $22.43 |
| Change ($) | 0.07 |
| Change (%) | 0.31% |
| Day's Open | 22.42 |
| Day's Range | 22.42 - 23.21 |
| Day's Volume | 372,491 |
| 52-Week Range | 10.47 - 30.65 |
If you are screening the market for high-return investments, you may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Por...
Meridian Bioscience (VIVO) closed at $22.43 in the latest trading session, marking a +1.72% move from the prior day.
CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021...
Meridian Bioscience (VIVO) closed the most recent trading day at $23.94, moving -1.4% from the previous trading session.
Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...
Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it ...
Is (VIVO) Outperforming Other Medical Stocks This Year?
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are advise...
Bull of the Day: Meridian Bioscience (VIVO)
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such inves...
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are advis...
Crocs (CROX), iRobot (IRBT), Sprouts Farmers Market (SFM), Meridian Bioscience (VIVO) & MEDIFAST (MED) are the top five companies boasting solid efficiency levels at present.
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such inves...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are advise...
As of late, it has definitely been a great time to be an investor in Meridian Bioscience, Inc. (VIVO).
CINCINNATI, March 08, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the lau...
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such invest...
CINCINNATI, March 04, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in t...
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are advised...
Meridian Bioscience (VIVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Profitability analysis is considered one of the best possible ways to assess the prospects of a company.
Is (VIVO) Outperforming Other Medical Stocks This Year?
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the...
After submitting a written response to the FDA's request for additional information on Meridian Bioscience Inc's (NASDAQ: VIVO) Revogene SARS-CoV-2 test on February 16 and further discussions with the F...
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its applic...
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such in...
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are advised...
Cash indicates a company's true financial health. It offers the flexibility to make decisions, the means to make potential investments and the fuel to run its growth engine.
CINCINNATI, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application f...
Meridian Bioscience (VIVO) could produce exceptional returns because of its solid growth attributes.
Top Ranked Momentum Stocks to Buy for February 12th
Bull of the Day: Meridian Bioscience (VIVO)
New Strong Buy Stocks for February 10th
Low-beta stocks may be able to help sail through the choppy market conditions.
Is (VIVO) Outperforming Other Medical Stocks This Year?
Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical com...
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 54.76% and 1.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Meridian Bioscience (NASDAQ:VIVO) moved higher by 5.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 550.00% year over year to $0....
CINCINNATI, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020.
Meridian (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase p...
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
CINCINNATI, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it ...
In the latest trading session, Meridian Bioscience (VIVO) closed at $22.10, marking a +1.33% move from the previous day.
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
Meridian Bioscience (VIVO) closed at $22.60 in the latest trading session, marking a -0.88% move from the prior day.
About VIVO
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid im... [Read more...]
| Industry Diagnostics & Research | |
| CEO John Kenny | Employees 750 |
| Stock Exchange NASDAQ | Ticker Symbol VIVO |
Financial Performance
In 2020, VIVO's revenue was $253.67 million, an increase of 26.19% compared to the previous year's $201.01 million. Earnings were $46.19 million, an increase of 89.43%.
Analyst Forecasts
According to 4 analysts, the average rating for VIVO stock is "Buy." The 12-month stock price forecast is 32.67, which is an increase of 45.20% from the latest price.